Learn how we supported a global IVD manufacturer in achieving IVDR compliance for their multiplex STI PCR test, ensuring timely CE-marking and future regulatory confidence.
Our client is a global IVD manufacturer, known for its expertise in molecular diagnostics and point-of-care solutions. With a strong presence in infectious disease testing and a clear ambition to expand across Europe, the company continues to push the boundaries of innovation in the in vitro diagnostics space.
As part of its growing portfolio, the client developed a fully automated multiplex real-time PCR panel capable of detecting eight common sexually transmitted infection (STI) pathogens. To bring this product to the European market, they needed to obtain CE-marking under the In Vitro Diagnostic Regulation (IVDR).
While the technical innovation was sound, the clinical performance study required for IVDR compliance presented a unique challenge. The need to collect sufficient samples for multiple low-prevalence pathogens made the study both logistically and scientifically complex. On top of that, staying within timelines was critical.
QbD Group stepped in with a hands-on and strategic approach, tailored to the client’s needs. We started by shaping a clinical performance evaluation plan that met all IVDR requirements, without overcomplicating the operational side.
Working closely with the client, we calculated a sample size that was both statistically solid and feasible in real-world conditions. We then selected study sites across the EU that provided access to the right patient populations, improving enrolment feasibility from the outset.
By combining regulatory know-how with pragmatic execution, we helped the client successfully gather the clinical evidence needed for IVDR compliance. The study remained on schedule, enabling a timely CE-marking submission.
Just as importantly, the collaboration laid a strong foundation for future IVDR submissions, giving the client greater confidence moving forward.
This project not only supported the launch of an innovative diagnostic tool, but it also reinforced the client’s position as a trusted player in the European molecular diagnostics market.
继续阅读
成功案例Fast-track your IVDR market access with our expertise. We help clients navigate regulatory hurdles to launch innovative diagnostic solutions efficiently and effectively.
阅读更多
成功案例Accelerate your market entry with our integrated IVDR and WHO strategy, ensuring compliance while minimizing costs and sample size for diagnostic tests.
阅读更多
成功案例QbD Group helped a biotech company complete 5 site qualification visits in just 3 weeks enabling a timely and compliant clinical trial submission.
阅读更多